AR061438A1 - Derivados de entacapone - Google Patents

Derivados de entacapone

Info

Publication number
AR061438A1
AR061438A1 ARP070102558A ARP070102558A AR061438A1 AR 061438 A1 AR061438 A1 AR 061438A1 AR P070102558 A ARP070102558 A AR P070102558A AR P070102558 A ARP070102558 A AR P070102558A AR 061438 A1 AR061438 A1 AR 061438A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
members
alkenylene
aryl
Prior art date
Application number
ARP070102558A
Other languages
English (en)
Inventor
Fritz Paar
Klaus Hansen
Robert Kraemer
Thomas Lauterbach
Petra Pfeiffer
Dirk Schmidt
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR061438A1 publication Critical patent/AR061438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica que comprende uno o más derivados de entacapone y uno o más portadores farmacéuticamente aceptables, un proceso para producir la composicion farmacéutica, derivados específicos de entacapone, un proceso para la preparacion de derivados de entacapone, y el uso de los derivados de entacapone para la preparacion de un medicamento. Reivindicacion 1: Una composicion farmacéutica que comprende uno o más compuestos de la formula I o una sal del mismo en donde Y es azufre u oxígeno R1 es un grupo de la formula (2), R2 es H o un grupo de la formula (2) el cual puede ser el mismo o diferente que R1, cada R3 es independientemente alquilo-(C1-C20), (CR4R5) x -R6, alquileno-(C1-C20)-alcoxi - (C1-C20), alquenilo-(C2-C20) alquinilo - (C2-C20), alquileno-(C0-C20)-cicloalquilo-(C3-C18), alquileno-(C0-C20)-heterocicloalquilo-(3-18 miembros), alquileno-(C1-C20)-cicloalquenilo-(C3-C18), alquileno-(C0-C20)-heterocicloalquenilo-(3-18 miembros), alquileno-(C0-C20)-arilo-C6- C18), alquileno-(C0-C20)-heteroarilo-(5-18 miembros), alquenileno-(C2-C20)-cicloalquilo-(C3-C18), alquenileno-(C2-C20)-heterocicloalquilo- (3 a 18 miembros), alquenileno -(C2-C20)-cicloalquenilo-C3-C18) alquenileno, -C2C20 0-heterocicloalquenilo-(3- 18 miembros), alquenileno-(C2-C20)-arilo-C6-C18, o alquenileno - C2-C20-heteroarilo-(5-18 miembros) en donde el numero total de átomos de carbono de R3 es a lo sumo 30, Cada R4 y R5 son independientemente uno de otro seleccionados del grupo que consiste de H, alquilo, (C1-C20), alquileno -(C1-C20)-hidroxi, alquileno (C0-C20)-alcoxi -C1-C20, OH, alquileno-(C0-C20)-N(R7)(CO)-alquilo -C1-20, alquileno-C0-20-CON(R8)(R9),alquileno(C0-C20)-COO-alquilo-(C1-C20), alquileno-(C0-C20)-N(R10)R11), SO3R17, alquileno-(C0-C20)-arilo-(C6-C18), o alquileno-(C0-C20)-heteroarilo -(5-18 miembros), o R4 y R5 del mismo grupo (CR4R5) o R4 y R5 de diferentes grupos (CR4R5) pueden formar juntos un anillo carbocíclico o heterocíclico que tiene desde 3 a 6 átomos, adicionalmente, uno o más grupos (CR4R5) no adyacentes pueden estar reemplazados por O, CO, OCO, COO, CON(R19), N(R20)CO, o NR21, R6 es independientemente H, alquilo-(C1-C20) alquenilo - (C2-20), alquinilo (C2-C20), OH, O-alquilo-(C1-C8), o- alquileno-(C0-C8)-arilo-(C6-C14), CO-O-alquilo-(C1-C8), CO-N(R12)(R13), N(R14)CO-alquilo-(C1-C8), N(R15)(R16), SO3R18, alquileno -(C0- C20 )-heteroarilo-(5-18 miembros), o alquileno-(C0-C20)-arilo-(C6-C18), R7, R14, R17, R18, R19, R20, R21 son independientemente uno de otro H, o alquilo-(C1-C20), R8, R9, R10, R11, R12, R13, R15, R16 son independientemente uno de otro H, o alquilo-(C1-C20), R22 y R23 son independientemente seleccionados del grupo que consiste de H y alquilo-(C1-C15), y x es 1 a 14, en donde los grupos alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, cicloalquenilo, heterocicloalquenilo, alcoxi, arilo, heteroarilo, alquenileno y alquileno pueden estar insustituidos o adicionalmente sustituidos; y uno o más portadores farmacéuticamente aceptables.
ARP070102558A 2006-06-16 2007-06-12 Derivados de entacapone AR061438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06012394 2006-06-16

Publications (1)

Publication Number Publication Date
AR061438A1 true AR061438A1 (es) 2008-08-27

Family

ID=37199189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102558A AR061438A1 (es) 2006-06-16 2007-06-12 Derivados de entacapone

Country Status (4)

Country Link
US (1) US20080103191A1 (es)
AR (1) AR061438A1 (es)
TW (1) TW200817315A (es)
WO (1) WO2007144169A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084031A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a
TWI511299B (zh) * 2008-09-01 2015-12-01 Semiconductor Energy Lab 半導體裝置的製造方法
WO2010078494A2 (en) 2008-12-31 2010-07-08 Dow Global Technologies Inc. Procatalyst composition with substituted 1,2-phenylene aromatic diester internal donor and method
CN102482376B (zh) 2008-12-31 2014-04-02 陶氏环球技术有限责任公司 丙烯无规共聚物组合物，制品及方法
WO2011008675A2 (en) * 2009-07-15 2011-01-20 Chadeayne Andrew R Catecholamine compounds, compositions, and formulations, and methods of using the same
JP5878473B2 (ja) * 2009-12-02 2016-03-08 ダブリュー・アール・グレイス・アンド・カンパニー−コネチカット ポリプロピレン製造のための触媒における内部供与体としての二原子架橋ジカーボネート化合物
MY158466A (en) * 2009-12-02 2016-10-14 Grace W R & Co Three and four atom bridged dicarbonate compounds as internal donors in catalysts for polypropylene manufacture
CN103787917A (zh) * 2012-11-01 2014-05-14 南京化工职业技术学院 一种改进的n,n-二甲基氰基乙酰胺的合成工艺
CN107011313B (zh) * 2016-01-27 2021-11-30 天士力医药集团股份有限公司 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用
WO2018036498A1 (en) 2016-08-24 2018-03-01 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
CN110225751A (zh) * 2016-08-24 2019-09-10 北京生命科学研究所 用于治疗损伤的与恩他卡朋相关的化合物
CN108440340B (zh) * 2017-02-16 2022-08-26 北京伊斯康科技有限公司 一种制备恩他卡朋的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE92535C (es) *
DE72806C (de) * Firma Dr. F. VON HEYDEN NACHFOLGER in Radebeul bei Dresden Verfahren zur Darstellung von Kohlensäureestern des Brenzcatechins und seiner Monoalkyläther
US2455653A (en) * 1945-02-21 1948-12-07 Goodrich Co B F Di(alkenyl carbonato) aromatic compounds and polymers thereof
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof

Also Published As

Publication number Publication date
WO2007144169A2 (en) 2007-12-21
TW200817315A (en) 2008-04-16
US20080103191A1 (en) 2008-05-01
WO2007144169A3 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
AR061438A1 (es) Derivados de entacapone
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
AR061584A1 (es) Uso de 2-aminotetralinas sustituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR064420A1 (es) Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR048820A1 (es) Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3)
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
PE20080144A1 (es) Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa
HK1111999A1 (en) Spiroketal derivative and use thereof as diabetic medicine
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
AR065863A1 (es) Derivados de imidazolidinona
NZ598544A (en) Ascorbic acid derivatives as antiviral agents for treating viral conditions in plants
RU2010137862A (ru) Производное бициклоамина
ES2539722T3 (es) Compuesto de tetrahidrobenzotiofeno
AR081495A1 (es) Compuestos para el tratamiento de la hepatitis c

Legal Events

Date Code Title Description
FA Abandonment or withdrawal